Correspondence

The University of Kansas Medical Center
Kansas City, Kansas

ORCID IDs: 0000-0002-3177-3992 (C.D.B.); 0000-0001-9092-4861 (M.A.S.).

*These authors contributed equally to this work as first authors.
†Corresponding author (e-mail: cbengtson@kumc.edu).

References

1. Moran A, Becker D, Casella SJ, Gottlieb PA, Kirkman MS, Marshall BC, et al.; CFTR Consensus Conference Committee. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 2010;33:2677–2683.

2. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005;146: 681–687.

3. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000;162:891–895.

4. Ramsay BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al.; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663–1672.

5. Middleton PG, Mall MA, D et al.; VX17-445-102 Study Group. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 2019;381: 1809–1819.

6. Volkova N, Moya K, Evans J, Campbell D, Tian S, Simard C, et al. Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries. J Cyst Fibros 2020;19:68–79.

7. Taabari R, Elyashar HI, Cymberknown MC, Breuer O, Armoni S, Livnat G, et al. CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation. J Cyst Fibros 2016;15: e25–e27.

8. Knapp EA, Fink AK, Goss CH, Sewall A, Ostrenga J, Dowd C, et al. The Cystic Fibrosis Foundation Patient Registry: design and methods of a national observational disease registry. Ann Am Thorac Soc 2016;13: 1173–1179.

9. Oliveira L, Nave V, Garcia S, Perceval M, Rabilloud M, Durieu I, et al. Adherence to lumacaftor-ivacaftor therapy in patients with cystic fibrosis in France. J Cyst Fibros 2020;19:402–406.

Copyright © 2021 by the American Thoracic Society

To the Editor:

I read with interest the article by Hua-Huy and colleagues (1) describing an important finding of significantly raised levels of nasal nitric oxide (NO) during the recovery phase (≥6 wk to 5 mo) after complete resolution of coronavirus disease (COVID-19)–related anosmia (1). Interestingly, the nasal NO levels were significantly greater in patients with COVID-19 who developed anosmia than those who had preserved olfaction (1). I believe the authors observations are of great clinicopathological significance to understand the process of COVID-19–induced anosmia and its recovery, but the findings may not signify persistent inflammation or risk for progression to chronic rhinosinusitis disease (CRS).

Lower levels of nasal NO have been consistently found in patients with CRS; nasal NO levels are inversely related with the rhinosinusitis disability index (2). Conversely, increasing levels of nasal NO are often considered as a marker of recovery from CRS and success of treatment (2). Therefore, the higher measured levels of nasal NO observed in COVID-19 following recovery of anosmia (1) should not be considered as a risk factor for progression to CRS; instead, it appears to correlate with the process of recovery of olfaction. I, herein, propose an alternate hypothesis for the authors’ findings that can better explain the clinical pathophysiology of COVID-19–associated anosmia.

During the early phase of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of sustentacular cells and ciliated nasal epithelial cells, most individuals possibly develop effective innate immune responses in the nasal epithelium with limited infectivity of the lower airways and milder disease (3). However, the IFNs, so produced, can induce the expression of indoleamine 2,3-dioxygenase (IDO) activity on the nasal epithelial and endothelial cells, without widespread epithelial cell damage (4, 5). As a result, in SARS-CoV-2 infection, the tryptophan catabolism in the nasal epithelium may be diverted toward kynurenine pathways. The finding that Influenza A virus induces IDO expression, resulting in tryptophan depletion and rise in kynurenine levels in nasal epithelial cells after infection in air–liquid interface model, supports the above arguments (6).

Interestingly, SARS-CoV-2 infection is associated with increased levels of neurotrophic metabolites with glutaminergic activity: 3-hydroxykynurenine (3-HK), quinolinic acid (QA), and anthranilic acid; however, the neuroprotective by-products such as kynurenic acid and xanthurenic acid that possess glutamate antagonistic and α-7 nicotinic receptor inhibitory actions are decreased (7). I believe that from the olfactory epithelium, the locally generated 3-HK and QA reach the olfactory bulb (OB) via the transmucosal route. As the olfactory epithelium and OB-neurons have high N-methyl D-aspartate receptor expression (8), 3-HK and QA can induce direct neuronal injury resulting in anosmia (Figures 1A and 1B). Interestingly, bilateral administration of glutamate agonist, N-methyl D-aspartate, in the OB induces olfactory dysfunction by direct neurotoxicity with a spontaneous recovery 2 weeks after excitotoxicity lesion of the OBs (8). This characteristically correlates with the duration of anosmia in patients with COVID-19 (1). Importantly, elevated IDO activity inhibits NOS (NO synthase) and vice versa (9). Thus, recovery of smell in patients with COVID-19 may be due to the resolution of elevated IDO expression and concurrent increases in NO production (Figure 1C).

Based on the above arguments, I propose that the local nasal inflammation in the early phase of SARS-CoV-2 infection results in an injury to the olfactory neurons with concurrent decrease in nasal NO levels. However, from the evidence that, irrespective of the
etiology (inflammatory or noninflammatory), the nasal NO levels decrease in patients with decreased sense of smell (10), one can conclude that the lower nasal NO levels in patients with olfactory loss are more closely linked to the injury of olfactory sensory neurons rather than inflammation alone. Nonetheless, the recovery of smell loss is associated with the process of neurogenesis that involves an increase in the expression of inducible NOS in the basal progenitor cells secondary to the stimulation by leukemia inhibitory factor.

**Figure 1.** (A and B) Schematic representation of the mechanisms of anosmia in coronavirus disease (COVID-19). (C) Mechanisms linking increase in nasal nitric oxide levels with neurogenesis and recovery of smell in COVID-19. 3-HK = 3-hydroxykynurenine; ACE2 = angiotensin converting enzyme 2; GBC = global basal cell; HBC = horizontal basal cell; IDO = indoleamine 2,3-dioxygenase; iNOS = inducible nitric oxide synthase; KA = kynurenic acid; LIF = leukemia inhibitory factor; NAD = nicotinamide adenine dinucleotide; NMDA-R = N-methyl D-aspartate; NO = nitric oxide; NOS = nitric oxide synthase; QA = quinolinic acid; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; TNF-α = tumor necrosis factor α; XA = xanthurenic acid.
referred to the injured neurons (11) (Figure 1C). The increase in nasal NO levels during the recovery phase from rhinitis-induced inflammation and anosmia is already well evident (2); I believe this can secondarily be due to the normalization of tryptophan catabolism. Overall, the high nasal NO levels should not be considered as a simple marker of persistent inflammation and a risk factor for CRS in patients recovering from COVID-19–induced anosmia.

In conclusion, the proposed hypothesis explains why patients with COVID-19 with anosmia develop less severe disease than those with preserved olfaction and why higher nasal NO levels were evident in patients with COVID-19 after recovery of anosmia (1). I believe measuring the levels of nasal NO in patients with COVID-19 during the acute phase of anosmia and in patients with postacute COVID-19 syndrome with persistent anosmia could provide further understanding about the olfactory–nasal NO link in COVID-19.

Author disclosures are available with the text of this letter at www.atsjournals.org.

Amit Jain, M.D.*
Cleveland Clinic Abu Dhabi
Abu Dhabi, United Arab Emirates

ORCID ID: 0000-0002-0012-9491 (A.J.).

*Corresponding author (e-mail: amitvasujain@gmail.com).

References

1. Hua-Huy T, Lorut C, Aubourg F, Morbieu C, Marey J, Texereau J, et al. Persistent nasal inflammation 5 months after acute anosmia in patients with COVID-19 [letter]. Am J Respir Crit Care Med 2021;203:1319–1322.

2. Landis BN, Lacroix J-S. Olfactory function and nasal nitric oxide. Curr Opin Otolaryngol Head Neck Surg 2009;17:18–22.

3. Porta-Essassam J, Núñez-Gil IJ, González García N, Fernandez-Perez C, Viana-Llamas MC, Eid OM, et al. COVID-19 anosmia and gustatory symptoms as a prognosis factor: a subanalysis of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry. Infection 2021;49:677–684.

4. Chilosi M, Poletti V, Ravaglia C, Rossi G, Dubini A, Piccioni S, et al. The pathogenic role of epithelial and endothelial cells in early-phase COVID-19 pneumonia: victims and partners in crime. Mod Pathol 2021;34:1444–1455.

5. Jain A, Doyle DJ. Stages or phenotypes? A critical look at COVID-19 pathophysiology. Intensive Care Med 2020;46:1494–1495.

6. Lin YT, Lin CF, Yeh TH. Influenza A virus infection induces indoleamine 2,3-dioxygenase (IDO) expression and modulates subsequent inflammatory mediators in nasal epithelial cells. Acta Otolaryngol 2020;140:149–156.

7. Lawler NG, Gray N, Kimhofer T, Boughton B, Gay M, Yang R, et al. Systemic perturbations in amine and kynurenine metabolism associated with acute SARS-CoV-2 infection and inflammatory cytokine responses. J Proteome Res 2021;20:2796–2811.

8. Marin C, Langdon C, Alobid I, Fuentes M, Bonastre M, Mullol J. Recovery of olfactory function after excitotoxic lesion of the olfactory bulbs is associated with increases in bulbary SIRT1 and SIRT4 expressions. Mol Neurobiol 2019;56:5643–5653.

9. Darcy CJ, Davis JS, Woodberry T, McNiel YR, Stephens DP, Yeo TW, et al. An observational cohort study of the kynurenine to tryptophan ratio in sepsis: association with impaired immune and microvascular function. PLoS ONE 2011;6:e21185.

10. Gupta N, Drusch J, Landis BN, Hummel T. Nasal nitric oxide levels do not allow for discrimination between olfactory loss due to various etiologies. Laryngoscope 2013;123:311–314.

11. Sultz L, Bacgalupo J. Role of nitric oxide during neurogenesis in the olfactory epithelium. Biol Res 2006;39:589–599.